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Abstract Intra-articular glucocorticoid injections are the rec-
ommended treatment for active arthritis, but accurate position-
ing of the needle may be challenging. Inexperienced physi-
cians might decide not to inject because an unsuccessful in-
jection impairs clinical outcome and may lead to complica-
tions; however, choosing not to inject may impair or delay the
best possible treatment. Here, we address this problem by
introducing a novel Bioimpedance Probe (BIP) Needle-
guidance method that was tested in a clinical study. The BIP
Needle was utilized for detection of synovial fluid. It measures
real-time bioimpedance spectra and identifies when the needle
tip is in contact with the synovial fluid. Injections into 80
joints with active arthritis were performed by an experienced
rheumatologist using the BIP Needle. The location of the BIP
Needle was ensured by aspiration of synovial fluid, absence of
resistance during injection, and/or using real-time ultrasound
imaging. Sensitivity and specificity of the device for synovial
fluid detection were 86 % (CI 75–93 %) and 85 % (CI 74–
92 %), respectively. The BIP Needles showed high spatial
resolution and differentiated the synovial fluid from the sur-
rounding tissues. However, lack of synovial fluid, anatomic
variability, and intra-articular structures challenged the tech-
nology. The BIP Needles provided adequate results in intra-
articular injections. Performance of the device was good even
in small joints, which may be the most difficult for inexperi-
enced physicians. Further performance improvement can be
expected when more data is collected for mathematical
models. Overall, this novel method showed potential to be
used in real-time needle guidance.
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Introduction
The main outcome target in the treatment of rheumatic arthri-
tis (RA) is full remission. Early control of inflammation with
disease-modifying antirheumatic drugs (DMARDs) and sys-
temic or intra-articular glucocorticoids (GCs) has been shown
to be effective in reaching remission [1]. GC injections are the
traditional treatment and are considered a safe and effective
method in treating RA [2, 3]. For example in gout, occurrence
of bacterial arthritis was only about 1 in 1000 punctures [4].
Active treatment of arthritis with GC injections has been
shown to retard radiological progression [5] and increase re-
mission rates [6].
Systemic treatment is often started using synthetic DMARDs
(sDMARDs) and active inflammation is kept in control with
intra-articular GC injections. During the past few years, biolog-
ical DMARDs (bDMARDs) have been studied intensively and
have been found to be effective in patients who do not respond
to sDMARDs. However, in most cases, sDMARDs are as ef-
fective as bDMARDs but significantly less costly [7, 8].
Regardless of the type of DMARD used, intra-articular GC
injections are recommended as part of the treatment of active
arthritis [9, 10]. They should not be dismissed, because
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neglecting use of GC injections may impair remission rates and
lower quality of life [6].
Despite the recommendations, patients may not receive GCs
when needed. One problem with using GC intra-articular injec-
tions is difficulty in determining the exact positioning of the
needle. The success rate in needle positioning for injections
guided only by clinical palpation is around 30–80 % [11, 12].
Real-time needle-guidance methods have been developed for
more accurate needle location. For example, use of ultrasonog-
raphy significantly increased the accuracy, from 32 to 97 %, in
the study of Balint et al. [11]. A newer method for needle guid-
ance is utilization of bioimpedance [13].
We report our results from a clinical study of a novel
bioimpedance-based needle-guidance method, which we term
Bioimpedance Probe (BIP) Needle. This method provides real-
time feedback to the physician during the injection and alerts
when the needle is in contact with synovial fluid. The aim is that
an experienced physician can increase the accuracy of their
needle positioning, while an inexperienced physician is assisted
with the procedure and therefore encouraged to use the injec-
tions. This is the first time, to our knowledge, that a
bioimpedance-based, tissue-sensing technology has been uti-
lized in intra-articular GC injections in patients with RA and
other arthritides. The study assessed the needle-guidance meth-
od for detection of synovial fluid.
Materials and methods
Study design
This clinical study was authorized by the Ethics Committee of
the Department of Medicine, Helsinki University Central
Hospital (79/13/03/01/2014). The procedures followed were
in accordance with the ethical standards of the responsible
committee on human experimentation and with the Helsinki
Declaration of 1975, as revised in 1983. All participants pro-
vided written informed consent.
The study was performed in the rheumatology outpatient
clinic of Helsinki University Central Hospital, which is
Finland’s largest such clinic. The patients were treated
according to normal treatment strategies. The intra-articular
injection procedure did not differ from that used in normal
practice, except for the use of the BIP Needle and a
bioimpedance analyzer, which detected synovial fluid during
the injection.
Before the injection, the target joint was clinically evaluat-
ed, including ultrasonography examination, and the most suit-
able injection site was identified. An experienced rheumatol-
ogist performed the injection and evaluated the performance
of the measurement device. Small joints were injected with
24G needles and larger joints with 22G needles. When the
target was reached, correct needle placement was confirmed
by aspiration of synovial fluid, ultrasound imaging, and/or
absence of resistance when injecting GC. Injections were ex-
cluded from the statistical analysis (n=8) if there was needle
placement uncertainty, clear user error, a connection error in
the cable, or a problem with the power supply. Regardless of
the operation of the measurement device, the GC injection
was given when clinically indicated.
The final numbers of injections included in the statistical
analysis were 15 and 57 with the 22G and 24G needles, re-
spectively, giving a total of 72 injections. Three injections did
not reach the synovial cavity, as verified by ultrasound imag-
ing, but were included in the analysis.
The rheumatologist filled in a case report form immediately
after each treatment and evaluated the performance of the
device. The form included both a written description and a
table for true-/false-positive and true-/false-negative detection
of the target. The injection was treated as a whole, meaning
that even a single false event was sufficient to determine the
whole detection false, even thoughmost of the time the device
functioned correctly.
Patients
All suitable adult patients that came to the clinic for GC injec-
tion were given the opportunity to join the study. Thus, the test
subjects were randomly chosen and represented the usual dis-
tribution of patients in this rheumatology department.
The mean age of the patients (N=51) was 53 years (range
19–84 years), and 74 % were female. The diagnoses and
Table 1 Baseline characteristics
(80 injections) Diagnosis Disease duration (year)
Rheumatoid arthritis (RF+) 44 0–1 10
Rheumatoid arthritis (RF−) 10 2–5 22
Oligoarthritis seronegative 10 6–10 14
Chronic juvenile arthritis 5 11– 34
Others: ankylosing spondylitis (4), Sjögren syndrome
(2), reactive arthritis (2), and psoriatic arthritis (3)
11
RF rheumatoid factor
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disease durations are presented in Table 1. Each injection was
studied individually regardless of the other possible injections
listed, so that the data are based on the number of injections
rather than the number of patients (some patients received
multiple injections). Thus, the statistics of the test subject rep-
resent the statistics of the studied injections.
The distribution of the joints injected is shown in Table 2.
Knees were excluded from the study because they were con-
sidered easy to inject and, therefore, were meaningless for
assessing later practical use of BIP Needle. The total number
of injected joints was 80 joints in 51 patients; thus, the mean
number of injected joints was 1.57 per patient.
Measurement system
Measurements were performed using the BIP Needle (see
Fig. 1) connected to the measurement device and tissue-
classification software [14]. The BIP Needle is a standard
22G or 24G hypodermic needle, but inside the needle is a
removable BIP stylet. During needle positioning, the BIP is
kept inside the needle, enabling measurement from the needle
tip.When the target is reached, the BIP is removed and the GC
injected.
The BIP Needle is connected to a measurement de-
vice and a laptop containing tissue-classification soft-
ware. The software parameters are optimized for each
needle type, that is, there are specific mathematical
models for the 22G and 24G needles. The bioimpedance
spectrum is measured at multiple frequencies in the ki-
lohertz range. Based on the measured impedance and
phase angle values, the software classifies the tissue in
which the needle tip is located, using the mathematical
model. When the target tissue is detected, the device
beeps, providing a clear feedback to the physician dur-
ing the injection.
The original mathematical model was based on animal
studies with pigs, and then the parameters were fine-tuned
during an exploratory phase clinical study [14, 15]. In that
study, two target classes for synovial fluid were created:
BPure^ and BComplex.^ The Pure class represents the case
when the needle tip is in good contact with the pure, well-
conducting synovial fluid; such data are obtained from, for
example, knees with effusion. In the exploratory phase, it
was noted that in small and rheumatic joints with small
amounts of synovial fluid, the bioimpedance spectra differed
from the pure synovial fluid; therefore, a new class labeled
Complex was determined. Class Complex is less certain
detection.
Statistical analysis
Sensitivity, specificity, positive predictive power, and negative
predictive power were calculated from the results. Detection
of Pure and Complex cases were treated in the same manner,
e.g., a case was considered true positive if the device returned
either a Pure or Complex result when the synovial fluid was
reached, whereas if the device returned a Pure or Complex
result when the needle was not in the synovial fluid, the whole
injection was considered false positive.
Confidence interval was calculated for 95 % certainty in-
tervals using the Clopper-Pearson method and binomial dis-
tribution. Two different needle types were used and different
joints injected, but statistically it is relevant to consider only
the pooled results.
Results
The device functioned correctly in 74 % (53/72) of injections
(Table 3). It detected either Pure, Complex, or Complex plus
Pure synovial fluid in successful injections. In three injections,
the needle did not reach the synovial cavity and the device did
not provide any detection. Most of the detections were
Complex detections. Pure detections were obtained in 29 %
(21/72) of correct detections, but during these injections,
Complex detections also occurred frequently. The BIP
Needle was sensitive to spatial placement, and even small
movements affected the classification results. Normal practice
of the clinic was followed, and no bacterial contamination
after injection or any other safety issues or risks appeared
during this clinical study.
Table 2 Injected joints (N= 80)
and correct functioning of the
device in different joints
Target joint Injected Included to analysis Correct functioning
Wrist 26 24 18
Ankle 14 12 8
MCP joint 12 12 9
MTP joint 11 9 9
Hip 6 6 4
Others: finger (4), shoulder (4), and elbow (3) 11 9 5
MCP metacarpophalangeal, MTP metatarsophalangeal
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Typically, large joints with excess synovial fluid provided
Pure detections, while Complex detections occurred in small
joints. Figure 2 presents three example cases of injections, into
small, medium, and large joints. The figure shows the propor-
tion of detections within 1-s time intervals as a bar plot, and
the median filtered impedance value as a line plot. The imped-
ance spectra are needed for the sophisticated mathematical
model, but single-frequency impedance provides a rough idea
of the properties of the tissue. In each case, the impedance is
high at the beginning of the injection because the needle tip is
in poorly conducting tissue. As the needle proceeds through
the tissue, the impedance value varies according to the tissue
type and tissue structures. Motion artifacts also cause fluctua-
tions in the values. Finally, when the needle is in the synovial
fluid, the impedance value is low and the device provides the
detection feedback.
Movement inside the synovial cavity also affected the
impedance, probably due to the inner structures of the
joint. For example, in wrist injection (Fig. 2), the syno-
vial cavity was attained quickly, contact was good, and
detection result was Pure. However, Complex detection
then occurred, probably as a result of needle movement.
When the needle position was changed further, Pure
detection was achieved again. Hip injection took a lon-
ger time to complete than other injections, but when the
synovial cavity was reached, the detection was clear and
Pure was detected immediately. In metacarpophalangeal
(MCP) injection, only Complex detections were
achieved, which was typical of small-joint injections.
In these joints, the cavity size and amount of synovial
fluid are small, which both influence measurement
results.
The classification model for 24G needles detected synovial
fluid in 50 injections when the needle was in the joint cavity.
In 10 injections, the device provided false-positive detection;
the target joints in these cases were five wrists, three ankles
and one elbow, and one MCP. In many cases, these false
detections were very short and occurred with rapid needle
movements.
All detections except one were correct with the 22G
needles. In four injections (one elbow joint, one ankle
joint, and two hip joints), the needle tip was in the joint
cavity but the device did not beep. Correct functioning
of the device in different joints is listed specifically in
Table 2.
When the results from both needles were combined
together, the sensitivity was found to be 86 % and the
specificity 85 %. These and other statistics with confi-
dence intervals are shown in Table 4. The calculated
statistical performance values are on the same level with
each other. According to the confidence intervals, even
the worst performance result was on the level of 75 %.
Discussion
This study has shown that synovial fluid differs electrically
from surrounding tissues. However, impedance varies even
inside the synovial capsule indicating that the size of the joint,
Fig. 1 24G injection needle with bioimpedance probe (BIP) stylet
connected to the measurement device. Miniature electrode configuration
enables highly local and spatially precise measurement from the very tip
of the needle. Reproduced from [14]
Table 3 Confusion matrix of
results from different types of
needles
Reality
Classification Inside the synovial cavity Outside the synovial cavity
Synovial fluid detection
22G BIP needles
Synovial fluid detected 9 (69 %) 1 (7 %)
Synovial fluid not detected 4 (31 %) 14 (93 %)
Number of injections 13 15
24G BIP needles
Synovial fluid detected 50 (89 %) 10 (18 %)
Synovial fluid not detected 6 (11 %) 47 (82 %)
Number of injections 56 57
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the amount of synovial fluid, the amount of inflammation, and
the presence of different abnormalities may affect the
bioimpedance properties, challenging the technology.
With 22G needles, specificity was good at 93 % (68–
100 %), but the sensitivity needs to be improved. In 4 of 13
cases, the device did not detect synovial fluid even though the
needle tip is confirmed by ultrasonography to be in the joint
cavity. This was probably due to suboptimal classifier param-
eters. The original model was tuned in the explorative phase
with 11 injections, mainly in the knees. It seems likely that the
data were too limited for model creation and the model should
be updated using all of the new gathered data.
With 24G needles, sensitivity was good at 89% (78–96%).
False-negative cases were mostly due to software-related
sound issues. Careful inspection of the recorded data files
revealed that the system had detected synovial fluid at the
right time in six cases but no sounds were heard during these
events. In addition, the needle tip may have had poor contact
with well-conducting synovial fluid even inside the joint cav-
ity. There may have been poorly electrically conductive tissue
structures inside the joint cavity, such as the articular cartilage
surrounding the tip of the bones.
The performance comparison between different needle
types or different target joints is also interesting (Tables 2
and 3). However, the number of cases in subgroups was too
low, and therefore, reliable comparison cannot be made about
the true performance level in subgroups. Statistically, it is
relevant to consider only the pooled results. Nevertheless, ac-
curacy was highest in the toes, wrists, and fingers. In 9/9
injections into the metatarsophalangeal (MTP) joints, in 18/
24 injections into the wrists, and in 9/12 injections into the
MCP joints, the device functioned correctly. This is notable, as
the small joints are often difficult to inject for inexperienced
physicians.
The sensitivity of the system was good, but there were 10
false-positive events out of 58. In four cases, the system in-
correctly detected synovial fluid during penetration of the skin
or immediately underneath the skin. The duration of these
events was very short, usually 0.1 s or less. Based on the
recorded data, it seems that in some cases the bioimpedance
of subcutaneous structures strongly resembles that of synovial
fluid. This is likely caused by motion artifacts rather than
actual subcutaneous structures. As the false detection usually
occurs during skin penetration or immediately after it, false
detection can be easily disregarded by the operating physician.
Thus, in future use, a physician should consider the penetra-
tion depth together with the classification result.
Fig. 2 Example cases of
injections. Proportion of
detections within a 1-s time
interval are shown as a bar plot
and the impedance value as the
light grey line. Small joints
typically provided only Complex
detections and large joints
provided Pure detections. Needle
movements inside the joints
affected the measurement results
and classification
Table 4 Pooled classification results and statistical performance values




Positive predictive value 84.3 (73.6–91.9)
Negative predictive value 85.9 (75.6–93.0)
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In six cases, the reason for false-positive events was uncer-
tain. Most likely, puncturing even small blood vessels or bur-
sae produces brief but incorrect synovial fluid detections. It is
not clear whether reducing the likelihood of these events with-
out altering the sensitivity to real synovial fluid is possible.
The goal of treatment of early RA is remission. The
existing treatment strategy has been the active use of
sDMARDs with or without GCs. The newer bDMARDs have
improved the prognosis of treatment-resistant RA dramatical-
ly; however, the cost of these bDMARDs is very high com-
pared with older sDMARDs. In the study by Hørslev-Petersen
et al. [16], an aggressive intra-articular injection of triamcino-
lone (every swollen joint was injected) and sDMARD strategy
in early RA provided excellent 2-year clinical and radiological
disease control independent of adalimumab induction therapy.
Their study showed that good responses can be achieved in a
less costly manner by using sDMARDs in combination with
intra-articular injections.
The presented novel technology could increase the
use of intra-articular injections and as a result decrease
the total costs. In high-volume mass production, the
prices of tissue-sensing needle can be expected to reach
the level of current high-tier styleted needles. The cable
is reusable and can be sterilized as needed, and the
device can be disinfected; thus, both are intended to
long-term use. The bioimpedance analyzer has been de-
signed as a simple and cost-effective device. Overall,
the additional costs of the technology are expected to
be reasonable. Furthermore, more affordable medication
could more than compensate the additional costs of the
technology.
The latest analyzer device is suitable for complementary
use together with ultrasound. Complementary role could be
emphasized in the future by integrating bioimpedance func-
tions to ultrasound imaging devices. Bioimpedance-based
needle guidance could also be used independent of ultrasound
in health centers to encourage non-specialist physicians to
provide intra-articular routine treatment. Furthermore, it could
be used in home visits, since the device is so small that it fits
into a bag. The device is practical in training, because super-
vising physician can more easily monitor the puncture proce-
dure. In addition, the device enables recording the procedure
and assessing it afterwards.
To conclude, the device provided adequate results and there
were no safety issues during this study. Detection of synovial
fluid was indicated by an easy method that did not disturb the
injection procedure. The performance was good, especially in
small joints, which are usually the most difficult for inexperi-
enced physicians. It is also notable that this study was per-
formed specifically in arthritic joints and, therefore, reflects
the true clinical picture in practical cases. A better treatment
outcome can be achieved when physicians, with the help of
BIP Needles, inject actively arthritic joints.
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